Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
The University of Texas Health Science Center at San Antonio
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06446531CT.gov Prevention of Progression of Prediabetes, Obesity and CV Risk | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prediabetes Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Actos (this asset) | The University of Texas Health Science Center at San Antonio | P1 | CC · 43 |
| Metformin | Yu Chen | P4 | A |
| Liraglutide | Woman's | P4 | BBB |
| Exenatide | RenJi Hospital | P4 | BBB |
| Semaglutide | Esbjerg Hospital - University Hospital of Southern Denmark | P4 | BBB |
| Empagliflozin | The University of Texas Health Science Center at San Antonio | P4 | BBB |
| Sitagliptin | Vanderbilt University Medical Center | P4 | BB |
| Pioglitazone | VA Office of Research and Development | P4 | BB |
| Dapagliflozin | Centro Medico Nacional Siglo XXI IMSS | P2/3 | BB |
+42 more in the Prediabetes Syndrome cohort
Other indications for Actos
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | B · 62 |
| Cardiovascular Disorder | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Actos in Prediabetes Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/actos-prediabetes-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →